DENVER, April 08, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients ...
FDA approves SeaStar Medical's SCD-ADULT study for treating acute heart failure with renal issues, funded by a $3.6 million NIH grant. SeaStar Medical Holding Corporation announced that the U.S. FDA ...
SeaStar Medical Holdings, a medtech company developing solutions to reduce the consequences of hyperinflammation on vital organs, recently announced it had obtained FDA Breakthrough Device Designation ...
SeaStar Medical Holding Corporation (NASDAQ:ICU) shares are trading higher on Thursday, on continued strength after the company received FDA Breakthrough Device Designation for its cell-directed ...
Interim study data show that SCD treatment is safe to use in pediatric patients with Acute Kidney Injury (AKI) requiring continuous kidney replacement therapy (CKRT) The SCD is currently being ...
Enables standardized inpatient hospital billing for QUELIMMUNE® (SCD-PED) therapyUniversal code paves the way for billing of future potential ...
DENVER, Oct. 18, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results